Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade

2 Jan 2024

Abstract excerpt

Since the advent of immune checkpoint blockade (ICB), there has been substantial interest in identifying biomarkers of response to facilitate treatment personalization for patients with various cancers. Tumor mutational burden (TMB) has received considerable attention as a validated biomarker of ICB response, which resulted in the 2020 FDA approval for the use of high TMB (≥10 mutations per megabase of DNA) as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38167869
DOI: 10.1038/s41698-023-00492-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockadePMID 38167869Read ↗

Tumor aneuploidy predicts survival following immunotherapy across multiple cancersSemantic proximity Read ↗

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapySemantic proximity Read ↗

Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterationsSemantic proximity Read ↗

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivitySemantic proximity Read ↗

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancerSemantic proximity Read ↗

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read ↗

Specific Aneuploidies Predict Immune Evasion and Poor Immunotherapy Response in MelanomaSemantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

Patterns of Aneuploidy and Signaling Consequences in CancerSemantic proximity Read ↗

Targeting vulnerabilities of aneuploid cells for cancer therapySemantic proximity Read ↗

Fraction of copy-number alterations significantly predicts survival following immunotherapy in a few cancersSemantic proximity Read ↗

Aneuploidy as a promoter and suppressor of malignant growth.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.